This paper uncovers legal challenges around psilocybin in various countries, highlighting regulatory frameworks and policy issues.
Psilocybin has emerged as a promising therapeutic agent for psychiatric and neurological disorders. However, its legal status varies significantly across countries, creating barriers for clinical use and research. This paper provides an international overview of the regulatory landscape governing medical psilocybin, highlighting key legal restrictions, policy challenges, and emerging frameworks that support clinical trials and compassionate use. Understanding these barriers is crucial for clinicians, researchers, and policymakers.
No takes yet. Share an insight, caveat, or question.
Mohamad Chweikh (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: